Denmark · Delayed Price · Currency is DKK Zealand Pharma Statistics
Total Valuation
Zealand Pharma has a market cap or net worth of DKK 37.72 billion. The enterprise value is 21.95 billion.
| Market Cap | 37.72B |
| Enterprise Value | 21.95B |
Important Dates
The last earnings date was Thursday, November 13, 2025.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Zealand Pharma has 70.29 million shares outstanding. The number of shares has increased by 12.73% in one year.
| Current Share Class | 70.29M |
| Shares Outstanding | 70.29M |
| Shares Change (YoY) | +12.73% |
| Shares Change (QoQ) | -1.97% |
| Owned by Insiders (%) | 0.38% |
| Owned by Institutions (%) | 41.07% |
| Float | 55.74M |
Valuation Ratios
The trailing PE ratio is 5.86.
| PE Ratio | 5.86 |
| Forward PE | n/a |
| PS Ratio | 4.12 |
| PB Ratio | 2.49 |
| P/TBV Ratio | 2.49 |
| P/FCF Ratio | 5.11 |
| P/OCF Ratio | 5.10 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.09, with an EV/FCF ratio of 2.98.
| EV / Earnings | 3.36 |
| EV / Sales | 2.40 |
| EV / EBITDA | 3.09 |
| EV / EBIT | 3.10 |
| EV / FCF | 2.98 |
Financial Position
The company has a current ratio of 14.10, with a Debt / Equity ratio of 0.03.
| Current Ratio | 14.10 |
| Quick Ratio | 14.10 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.06 |
| Debt / FCF | 0.06 |
| Interest Coverage | 233.70 |
Financial Efficiency
Return on equity (ROE) is 54.42% and return on invested capital (ROIC) is 35.58%.
| Return on Equity (ROE) | 54.42% |
| Return on Assets (ROA) | 33.44% |
| Return on Invested Capital (ROIC) | 35.58% |
| Return on Capital Employed (ROCE) | 45.27% |
| Revenue Per Employee | 20.81M |
| Profits Per Employee | 14.87M |
| Employee Count | 335 |
| Asset Turnover | 0.69 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Zealand Pharma has paid 572.87 million in taxes.
| Income Tax | 572.87M |
| Effective Tax Rate | 8.05% |
Stock Price Statistics
The stock price has decreased by -27.34% in the last 52 weeks. The beta is 0.54, so Zealand Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | -27.34% |
| 50-Day Moving Average | 484.11 |
| 200-Day Moving Average | 464.53 |
| Relative Strength Index (RSI) | 58.16 |
| Average Volume (20 Days) | 528,971 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Zealand Pharma had revenue of DKK 9.16 billion and earned 6.54 billion in profits. Earnings per share was 91.63.
| Revenue | 9.16B |
| Gross Profit | 9.15B |
| Operating Income | 7.07B |
| Pretax Income | 7.12B |
| Net Income | 6.54B |
| EBITDA | 7.08B |
| EBIT | 7.07B |
| Earnings Per Share (EPS) | 91.63 |
Balance Sheet
The company has 16.17 billion in cash and 406.44 million in debt, giving a net cash position of 15.76 billion or 224.27 per share.
| Cash & Cash Equivalents | 16.17B |
| Total Debt | 406.44M |
| Net Cash | 15.76B |
| Net Cash Per Share | 224.27 |
| Equity (Book Value) | 15.16B |
| Book Value Per Share | 215.72 |
| Working Capital | 15.44B |
Cash Flow
In the last 12 months, operating cash flow was 7.39 billion and capital expenditures -17.70 million, giving a free cash flow of 7.38 billion.
| Operating Cash Flow | 7.39B |
| Capital Expenditures | -17.70M |
| Free Cash Flow | 7.38B |
| FCF Per Share | 104.95 |
Margins
Gross margin is 99.99%, with operating and profit margins of 77.23% and 71.47%.
| Gross Margin | 99.99% |
| Operating Margin | 77.23% |
| Pretax Margin | 77.73% |
| Profit Margin | 71.47% |
| EBITDA Margin | 77.35% |
| EBIT Margin | 77.23% |
| FCF Margin | 80.57% |
Dividends & Yields
Zealand Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.73% |
| Shareholder Yield | -12.73% |
| Earnings Yield | 17.35% |
| FCF Yield | 19.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zealand Pharma has an Altman Z-Score of 17.81 and a Piotroski F-Score of 6.
| Altman Z-Score | 17.81 |
| Piotroski F-Score | 6 |